Quantum BioPharma
Innovating in Neurodegenerative Disease & Alcohol Health. Creators of unbuzzd™️ & Lucid-MS. Strong Execution. Diversified Treasury. NASDAQ symbol $QNTM
09/24/2026
Big News for unbuzzd™
Quantum BioPharma is pleased to announce the appointment of visionary entrepreneur Michael “Zappy” Zapolin as CEO of Unbuzzd Wellness Inc.
From Wall Street to pioneering internet ventures and next-generation wellness, Zappy brings decades of entrepreneurial experience, brand-building expertise and an extensive network to unbuzzd. His mandate: help finance and list Unbuzzd on a stock exchange and lead the ex*****on of a nationwide U.S. commercial marketing and product rollout.
Science-backed. Clinically validated. Built for a massive consumer opportunity.
unbuzzd™ is backed by a peer-reviewed clinical study supporting its ability to accelerate alcohol metabolism, restore mental clarity and reduce hangover symptoms.
As Zappy puts it: “I believe unbuzzd has the potential to help millions of lives, and I’m honored to help bring it forward.”
The next chapter of unbuzzd™ starts now.
🌐 Discover unbuzzd: unbuzzd.com
📈 Quantum BioPharma Ltd. — NASDAQ: QNTM | FRA: 0K91
Advancing Science. Saving Lives.
09/17/2026
🚀 NEW ANALYST COVERAGE FOR QUANTUM BIOPHARMA
Quantum BioPharma Ltd. (NASDAQ: QNTM) is pleased to announce that Rodman & Renshaw has initiated analyst coverage of the Company with a BUY rating and a US$8 price target.
This new coverage comes as Quantum BioPharma continues advancing its innovative therapeutic pipeline and pursuing its mission to develop transformative treatments in areas of significant unmet medical need.
🧬 BUY Rating
🎯 US$8 Price Target
📈 Independent Analyst Coverage
🔬 Advancing a Next-Generation Therapeutic Pipeline
The future of medicine starts with bold science.
Quantum BioPharma — Advancing Science. Saving Lives.
09/15/2026
Quantum BioPharma is heading to the ArcStone-Kingswood Growth Summit 2026 in Toronto! 🇨🇦
Quantum BioPharma Ltd. (NASDAQ: QNTM) (FSE: 0K91) is pleased to participate in the 3rd Annual ArcStone-Kingswood Growth Summit on September 16, 2026, at the Sheraton Centre Toronto Hotel.
Anthony Durkacz, Co-founder and Executive Co-chairman, will present Quantum BioPharma’s recent milestones and future growth strategy to investors, family offices and capital markets professionals.
The presentation comes at an important time for Quantum BioPharma following the FDA’s approval of the Investigational New Drug (IND) application for Lucid-MS, allowing the Company to advance its patented, first-in-class multiple sclerosis program into Phase 2 clinical trials in patients with progressive MS.
📍 Toronto, Ontario
📅 September 16, 2026
🏨 Sheraton Centre Toronto Hotel
Interested investors can register for a FREE PASS:
https://www.meetmax.com/sched/event_144037/investor_reg_new.html?attendee_role_id=ARCSTONE_ATTENDEE
08/31/2026
Quantum BioPharma (NASDAQ: QNTM). The company is advancing Lucid-21-302, a novel oral therapeutic candidate targeting protein arginine deiminase, or PAD, biology in multiple sclerosis. The program offers a differentiated approach centered on neuroprotection and myelin preservation, with several important development milestones ahead.
Please reach out directly or at [email protected] to request the full initiation report. More to come.
08/18/2026
3rd Party Article Mentioning Quantum BioPharma & Lucid-MS
NeurologyLive
https://neurologylive.com/view/fda-clears-phase-2-trial-demyelinating-agent-lucid-ms-progressive-multiple-sclerosis
$QNTM
Quantum BioPharma Receives United States FDA Clearance To Proceed with Lucid-MS Phase 2 Trial in Progressive Multiple Sclerosis
Major Regulatory Milestone Positions Company to Initiate Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Patented First-in-Class Neuroprotective Therapy Targeting Demyelination
Lucid-MS Advances Novel Disease-Modifying Approach Targeting Multi-Billion Dollar Progressive MS Market with Significant Unmet Medical Need Worldwide
https://www.globenewswire.com/news-release/2026/08/10/3341697/0/en/quantum-biopharma-receives-united-states-fda-clearance-to-proceed-with-lucid-ms-phase-2-trial-in-progressive-multiple-sclerosis.html
Most MS therapies modulate immunity. Quantum BioPharma’s investigational Lucid-MS is designed to address citrullination and myelin integrity through a differentiated, non-immunosuppressive approach.
Learn more: https://www.quantumbiopharma.com/lucid-ms
$QNTM
06/19/2026
Reframing MS starts with looking beyond the traditional autoimmune lens.
Quantum BioPharma’s Lucid-MS program is exploring neurodegenerative biology, myelin-related mechanisms, and a non-immunomodulatory research approach in multiple sclerosis.
Visit www.quantumbiopharma.com for more info.
06/08/2026
Multiple sclerosis remains a major unmet medical challenge.
Quantum BioPharma's investigational drug candidate, Lucid-MS, is a new chemical entity (NCE) being developed to target citrullination-driven demyelination through a non-immunosuppressive and non-immunomodulatory approach.
Research suggests excessive citrullination may alter myelin proteins and contribute to myelin damage, impacting nerve signaling.
✅ Novel mechanism under investigation
✅ Focused on demyelination biology
✅ Addressing an important unmet need in MS research
Lucid-MS is investigational and not approved by the FDA or Health Canada.
$QNTM
www.quantumbiopharma.com
06/05/2026
Quantum BioPharma continues advancing its Lucid-MS program with a focus on demyelination and neuroprotective pathways in Multiple Sclerosis.
Phase 1 complete. IND submitted for Phase 2 trial design.
Lucid-MS is investigational and not approved by FDA or Health Canada.
Sign up for email alerts : https://quantumbiopharma.com/email-alerts
$QNTM
Click here to claim your Sponsored Listing.
Category
Telephone
Address
1 Adelaide Street East Suite 801
Toronto, ON
M5C2V9